Corporate Update
MWN-AI** Summary
**Vystar Corporation Corporate Update - April 30, 2025**
Vystar Corporation (OTCQB: VYST), based in Boston, MA, has announced significant corporate developments following the final approval of its Form 15C-211 application. The company successfully transitioned from the Pink Sheets to the OTCQB Exchange, enhancing its stock's visibility and liquidity. Vystar currently has 17,400,614 shares outstanding, emphasizing its commitment to shareholders and an ongoing strategy for business improvement.
Key to this progress, Vystar's elimination of $5 million in lease liabilities and $6 million in loans reflects a strategic shift following the closure of its Rotmans furniture division. The company is refocusing its efforts on specialized manufacturing, targeting three main sectors: Vytex, RXAIR, and Fluid Energy Conversion (FEC).
Vytex emphasizes allergy-free natural rubber latex products, leveraging proprietary formulations to produce high-quality foam, gloves, and more. RXAIR focuses on air purification solutions for residential and medical applications, boasting FDA-approved devices that effectively eliminate airborne pathogens. Vystar has sold over 20,000 residential units and is poised for growth in the medical sector.
Fluid Energy Conversion (FEC) showcases innovative technology that converts liquid or gas flow into sound waves. This patented method enables various applications, including improving combustion processes and monitoring flow.
Moving forward, Vystar plans to expand its product lines while exploring mergers and acquisitions to enhance market share and operational efficiency. The company possesses a noteworthy $60 million loss carryforward, making it an attractive partner for potential synergies in future transactions.
As Vystar continues to leverage its unique offerings, shareholders can anticipate enhanced growth dynamics amidst a competitive landscape, with the promise of strategic developments on the horizon.
MWN-AI** Analysis
Vystar Corporation (OTCQB: VYST) has made significant recent strides by moving from the Pink Sheets to the more prestigious OTCQB Exchange and receiving final approval of its Form 15C-211 application. This transition enhances the company’s visibility, liquidity, and credibility, making it a more attractive option for potential investors.
With approximately 17.4 million shares outstanding, Vystar's restructuring and focus on core areas—Vytex, RXAIR, and Fluid Energy Conversion (FEC)—demonstrates a commitment to streamline operations and maximize shareholder value. The company's efforts to eliminate $11 million in debt further underscore its initiative to robustly position itself for future growth while reallocating resources to specialty manufacturing.
Vystar's proprietary products, particularly in Vytex latex and RXAIR air purification, offer competitive advantages rooted in patented technologies. The market for allergy-free latex products and medical-grade air purification units is on the rise, especially post-pandemic, where health and safety are paramount. Vystar has achieved FDA approvals for its offerings, cementing its status in the market, while the diverse applications of FEC technology present untapped opportunities across various industries.
Looking forward, Vystar's focus on M&A to expand market reach and operational efficiency, combined with its $60 million loss carryforward, makes it an attractive target for collaboration and strategic partnerships. Such synergies could enhance both market share and share price potential amid ongoing growth in health-focused and environmentally-friendly product sectors.
Investors should observe Vystar closely as it capitalizes on its strengthened financial standing and product innovations. The next earnings reports and news on M&A activity will be critical indicators of the company's trajectory. Caution is advised, however, as inherent risks are highlighted in their forward-looking statements, requiring due diligence from potential investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Boston, MA, April 30, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar received notice of final approval of its Form 15C-211 application. In addition, today the Company moved from the Pink Sheets to the OTCQB Exchange. The Company currently has 17,400,614 shares outstanding. This move marks an important milestone for Vystar as it allows for increased visibility and liquidity in the Company’s stock.
Formal notice from the OTCQB will be circulated on Monday. Vystar wants to thank the outstanding staff at the OTC Markets Group for their time and diligence working with Vystar in this process. The 15C-211 filing is a complex process that requires a multitude of reviews. The OTC Markets Group staff members worked meticulously with Vystar to ensure documentation was in order for final submission.
Vystar’s Moves For Shareholder Value
Vystar continues to move forward for the benefit of our shareholders. Vystar is working with its talented board members, larger shareholders and professions on a path of renewed intensity for success that it continues to maintain. This success and Vystar’s accomplishments are due to their tireless work.
Vystar’s promise and continued intent to streamline the business of the Company resulted in the removal of $5 million in Rotmans lease debt and an additional $6 million in loans from the Company’s obligations. This comports with Vystar’s closing of Rotmans, the Company’s furniture division. Vystar is redirecting its resources to its specialty manufacturing.
Vystar’s Concentrated Business
The three main areas of focus now are on Vytex , RXAIR , and Fluid Energy Conversion (FEC) . Vystar is confident it can succeed in spaces where it can make outstanding products that are protected by patents and copyrights. This precludes potential competitors from seeking to duplicate Vystar’s products.
Vytex Allergy Free Natural Rubber Latex – The Company owns the formulations and intellectual property that creates what Vystar believes to be the highest quality products as against any competitor’s products.
By way of example, Vystar can manufacture allergy and ammonia free natural latex products ranging from: (i) foam utilized in pillows, mattresses and toppers; (ii) gloves; (iii) condoms; and (iv) and other latex products. The Company believes its FDA approved products are unrivaled in the industry and maintains a substantial inventory warehoused in the United States.
RXAIR Residential and Medical Air Purification – Vystar has built a line of products for the home and medical facilities. The product lines range from a personal $500 unit to an industrial $6,000 unit for hospitals or similarly situated medical services. Vystar owns the patents and has achieved FDA approval, as well as EPA, CARB and other air purification certifications. Vystar has sold more than 20,000 residential and 400 hospital units RXAIR Video's . In addition, Vystar has invested in manufacturing and high-speed tooling for the units. These units are built to eliminate germs, viruses and bacteria. Vystar maintains a stockpile of more than a thousand units and replacement cartridges. Also important, Vystar is under a medical device exemption from the recent tariffs. RXAIR AIR PURIFIER ONLINE STORE .
FEC - The Hughes Reactor changes flow of liquid or gas into sound waves. The sound can be brought to powerful levels using a mechanism that has no moving parts. This allows the reactor the ability to harness the energy into various uses. The uses for this patented technology include: Flow Meter, hard water abatement, air purification, multiple dialysis applications and combustion enhancements for natural gas, biofuels, gasoline. This energy is powerful, clean, and controllable. It can be used to measure flow, to push forward chemical reactions such as combustion, or to mix chemicals together thoroughly and instantly. All of this technology is protected by Vystar’s intellectual property.
Moving Forward
The Company’s strategy is twofold. First, to ensure continued growth of its product lines and secondly, exploring M&A transactions that seek to match synergies with a counter-entity(ies) that would allow Vystar to expand its market share and gain further operational efficiency while greatly enhancing the share price.
With Vystar’s unique product lines and a $60 million loss carry forward, Vystar projects to be a tempting transaction for a “like for like” partner. Depending upon the partner, there is always the potential that a M&A transaction could include a spin-out of certain assets and result in more than one final public entity. Second, the Company continues to work to increase its current sales lines as well as utilize its protected products within new sectors of the economy.
Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.
Contact Vystar:
Distributor Opportunities: info@rxair.com
Media, Investors or To Partner with Vystar, Company Phone Number: (508) 791-9114
FAQ**
How does Vystar Corp VYST plan to leverage its move to the OTCQB Exchange to increase visibility and attract new investors?
With the recent removal of $11 million in debt, how does Vystar Corp VYST intend to reinvest those resources into its three main focus areas?
Can Vystar Corp VYST provide more details on the expected timeline and strategy for potential M&A transactions to expand market share?
What specific innovations or features set Vystar Corp VYST's Vytex and RXAIR products apart from competitors in the health and manufacturing sectors?
**MWN-AI FAQ is based on asking OpenAI questions about Vystar Corp (OTC: VYST).
NASDAQ: VYST
VYST Trading
15.63% G/L:
$0.0614 Last:
250 Volume:
$0.0531 Open:
